Back to Blog
Peptide Science••9 min read
MOTS-c Enters Phase 2a Human Trial for Prediabetes: What the Research Shows
MOTS-c — a peptide synthesized inside your own mitochondria — is now in Phase 2a human trials for prediabetes. Early data suggests it improves insulin sensitivity and metabolic flexibility without the side effects of pharmaceutical interventions.
PeptIQ Research Team
Editorial
#MOTS-C#prediabetes#insulin-resistance#mitochondria#metabolic health#Clinical Trials#longevity
Track Your Peptide Protocols
Use PeptIQ to log injections, calculate doses, access our peptide library, and optimize your protocols.
Download PeptIQ
